News und Analysen

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

GAMCO Investors, Inc. (“GAMCO”) (NYSE: GBL) today reported its operating results for the year ended December 31, 2021.

Full Year Results

Financial Highlights (Unaudited)

Year Ended

Iteris, Inc. (NASDAQ: ITI), the global leader in smart mobility infrastructure management, today reported financial results for its fiscal third quarter 2022 ended December 31, 2021. During the

Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, has launched a research study examining providers of marketing technology (MarTech), which is

Europäische Life-Sciences-Unternehmen investieren verstärkt in Analyse- und andere Technologien, um die Forschung und Entwicklung zu beschleunigen und patientenorientierte Innovationen

Ladder Capital Corp (NYSE: LADR) (“we,” “Ladder,” or the “Company”) will release its fourth quarter 2021 results on February 10, 2022 after the close of markets that day. The Company will host a

Jack in the Box Inc. (NASDAQ: JACK) (the “Company”) today announced that it has entered into a purchase agreement (the “Purchase Agreement”) under which one of its indirect, special purpose

Lawson Products, Inc. (NASDAQ: LAWS) (“Lawson” or the “Company"), a distributor of products and services to the MRO marketplace, today announced that it will report its results for the fourth

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation at the 11^th Annual Leerink Global Healthcare Conference (February

The Buckle, Inc. (NYSE: BKE) announced today that comparable store net sales, for stores open at least one year, for the 4-week period ended January 29, 2022 increased 4.2 percent from comparable

European life sciences companies are increasing their investments in analytics and other technologies to speed up research and development and drive patient-centric innovation, according to a new

ADTRAN, Inc., (NASDAQ:ADTN) (“ADTRAN” or the “Company”), today announced financial results for the fourth quarter of 2021. For the quarter, revenue was $154.2 million. Earnings for the fourth